Latest Tumor antigen Stories
It was once thought that the two communities of cells within a cancerous breast tumor â€“ fast-growing malignant cells and the normal cells that surround them â€“ existed independently, without interaction.
DES PLAINES, Ill., July 13 /PRNewswire-FirstCall/ -- Abbott announced today that it has entered into an agreement with GlaxoSmithKline (GSK) to develop an automated molecular diagnostic test, based on polymerase chain reaction (PCR) technology, intended to screen non-small cell lung cancer (NSCLC) tumors for expression of the MAGE-A3 antigen.
Researchers have identified a protein released by dying brain tumor cells that provides an effective way to gauge the effectiveness of a novel gene therapy treatment for brain cancer. The finding paves the way for a Phase 1 clinical trial expected to begin in late 2009.
Oncogenes are genes that when mutated or expressed in high concentrations can cause normal cells to become cancerous. Now research from Tel Aviv University is demonstrating that Ras, one of the first oncogenes discovered, has the power to heal as well as harm.
RARITAN, N.J., June 4 /PRNewswire/ -- Ortho Biotech Oncology Research & Development, a unit of Centocor Research & Development, Inc., today announced that it has entered into a five-year Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), with Steven A.
New approaches to gene therapy have been found that help eradicate brain tumors and boost the power of the immune system.
ERYtech Pharma, a French biotechnology company, will present very promising results from its original approach on antitumor vaccination at the 6th International Cancer Vaccine Symposium to be held in New York from October 28-30, 2008.
ImmunoCellular Therapeutics, a biotechnology company, has filed a provisional US patent application relating to its vaccine technology targeting cancer stem cells. The vaccine technology is exclusively licensed from Cedars-Sinai Medical Center.
ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBS), today announces a collaborative relationship with the University of North Carolina at Charlotte to evaluate ImmuneRegen's Viprovex as a possible cancer-vaccine adjuvant.
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.